On August 8, 2019, Liu Dengfeng, Director of the Department of Science and Technology of the National Health Commission, Zhang Hui, Director of the Biological Products Division of the Registration Department of the State Food and Drug Administration, and other leaders visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Biological Pharmaceutical Co., Ltd. for in-depth investigation. Bai Xianhong, Chairman of Baitai Bio, and Bai Yi, General Manager of Dongfang Baitai received warmly.

At the symposium, Chairman Bai Xianhong, on behalf of Baitai Bio and Dongfang Baitai, extended a warm welcome to Director Liu Dengfeng and his delegation. They thanked the Health Commission and the Food and Drug Administration for their support and concern for Dongfang Baitai and Baitai Bio in recent years. During the meeting, General Manager Bai Yi comprehensively introduced the work progress, positioning and future planning of the enterprise to all leaders. The antibody drug technology platform and R&D pipeline layout of Dongfang Baitai were mainly introduced. It fully demonstrates the technological development process and scientific research achievements of Dongfang Baitai in the past decade. Bai Yi, the general manager, mentioned that the project "Exendin-4 Fc antibody fusion protein (JY09) for long-term treatment of type II diabetes" under development by Dongfang Baitai is a long-term GLP-1 analog drug. It is one of the projects independently developed by Dongfang Baitai. It has the characteristics of safety, long duration and stable efficacy. It can be injected once every 7-14 days. Even multiple injections caused by forgetting the time of each injection during the normal half-life will not lead to the risk of hypoglycemia. It is a kind of protein macromolecular drug with safety guarantee. JY09 has the function of repairing islets and promoting insulin secretion. It has won the "triple" project of the national major new drug discovery project and the "priority review" project recommended by the National Health and Family Planning Commission. It has domestic and foreign invention patents of China, the United States, the European Union, Eurasia, Japan, South Korea, India, etc.

Dongfang Baitai has a high-tech R&D team. The main direction is to develop humanized monoclonal antibodies. More than 100 high-level professional antibody research and development teams have been established. More than half of them are doctors and masters, and many doctors have overseas study or technical management experience. The high-level R&D team has laid a solid foundation for the company's product technology leadership, technological innovation and sustainable development.

The team has undertaken a number of national and Beijing key research projects. It has won the first batch of engineering laboratories of the Beijing Development and Reform Commission - the Beijing Engineering Laboratory of Antibody Engineering, the Beijing Research Center for Genetic Engineering Antibody Drug Engineering Technology, and the international science and technology cooperation base of new antibody and therapeutic protein drugs, as well as the Beijing international science and technology cooperation base. It has also undertaken a number of key projects during the 11th and 12th Five Year Plan, such as the national "major new drug development", special projects of ministries and commissions, and the "863" plan.

Director Liu Dengfeng and Director Zhang Hui fully affirmed the development of Dongfang Baitai, and encouraged Dongfang Baitai to put the research and development of new drugs in an important position to rapidly improve the clinical trial results of drugs. And make detailed inquiries about the difficulties encountered in the development of the company. They mentioned that most of the drug production equipment needs to be imported, and the quality of the equipment should be strictly controlled, so as to prevent shoddy goods from being replaced by good ones, and make reassuring and conscientious drugs for Chinese people. Antibody drug R&D is characterized by high technology content, large capital investment, long R&D cycle and high risk. Relevant units will increase support and solutions, help enterprises retain high-tech talents, and ensure the smooth progress of high-tech R&D enterprises like Dongfang Baitai on the road of high-speed development to the greatest extent.

With the purpose of "pooling the strength of biomedicine, creating and enjoying the health of human life", Dongfang Baitai will continue to be committed to providing patients with high-quality and efficient antibody drugs, improving the quality of life of patients and escorting a healthy life.